Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-ICEBOAT: Neoadjuvant Tislelizumab + Chemo in Gastric Cancer
NCT06451211Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), sponsored by Sun Yat-sen University. Started May 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06451211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451211.